2026 Wegovy Medicare access guide

Does Medicare cover Wegovy in 2026? Bridge and Part D facts

Review current Medicare access paths for Wegovy injection and tablets, including the 2026 GLP-1 Bridge, Part D-coverable uses, prior authorization, $50 copay limits, denials, and compounded-product distinctions.

Educational guideUpdated August 7, 2026

A route-and-indication check for Medicare Wegovy access

Confirm the exact product and route: branded Wegovy injection or branded Wegovy tablets—not Ozempic, Rybelsus, or compounded semaglutide.

Document why Wegovy is prescribed: weight management, cardiovascular-risk reduction, qualifying MASH treatment, or another purpose.

Identify the correct pathway. Weight-management requests may use the Medicare GLP-1 Bridge; Part D-coverable uses stay with the Part D plan.

Obtain the clinician-submitted prior authorization and the written plan, Bridge, or pharmacy response instead of relying on an old formulary or another patient’s result.

Verify the exact package, participating pharmacy, authorization period, refill rules, medication copay, and any separate visit, laboratory, or service costs.

Direct answer

Medicare coverage for Wegovy in 2026 depends on why it is prescribed and which pathway applies. CMS currently lists Wegovy injection and tablets for eligible adults using the Medicare GLP-1 Bridge solely for weight management after clinician-submitted prior authorization; CMS describes a $50 copay for a monthly Bridge supply. Wegovy prescribed for a use coverable under basic Part D—such as reducing major cardiovascular-event risk in an adult with established cardiovascular disease and overweight or obesity, or Wegovy injection for qualifying noncirrhotic MASH with moderate-to-advanced fibrosis—must go through the Part D plan instead of the Bridge. A prescription, Part D enrollment, labeled indication, or qualifying BMI does not guarantee approval. Confirm the indication, route, current CMS criteria, plan or Bridge response, pharmacy claim, and total cost.

Two coverage pathways

Weight-management Bridge access and basic Part D coverage are different

CMS started the short-term Medicare GLP-1 Bridge on July 1, 2026 for eligible Part D beneficiaries seeking a listed GLP-1 drug solely to reduce excess body weight and maintain weight reduction. CMS separately says uses coverable under the basic Part D benefit must remain with the Part D plan. For Wegovy, CMS gives cardiovascular-risk reduction as a Part D example and also identifies qualifying noncirrhotic MASH with moderate-to-advanced liver fibrosis as Part D-coverable. The patient should not submit one pathway as a substitute for the other.

The current Bridge list includes Wegovy injection and tablets for qualifying weight-management use; it does not turn every Wegovy prescription into a covered claim.
The current manufacturer label gives both Wegovy injection and tablets cardiovascular-risk-reduction and adult weight-management contexts, while the qualifying MASH indication is specific to Wegovy injection.
A Bridge ineligibility result, Part D non-formulary response, missing prior authorization, pharmacy-processing problem, and excluded use are different access issues with different next steps.

Current Bridge criteria

A clinician must attest that the adult meets the current CMS requirements

CMS says a provider must submit a prior-authorization request confirming that Wegovy is prescribed for weight reduction and maintenance together with ongoing lifestyle modification consistent with the FDA-approved label. The published adult pathways include BMI at least 35; BMI at least 30 with one of the listed heart-failure, uncontrolled-hypertension, or chronic-kidney-disease conditions; or BMI at least 27 with one of the listed prediabetes or established cardiovascular conditions. The Bridge requires age 18 or older, even though the Wegovy injection label includes a weight-management indication for some patients age 12 and older. Current CMS criteria and the active authorization form should be checked before each request.

Do not estimate, change, or omit BMI, age, blood pressure, kidney stage, cardiovascular history, diagnosis, prior fills, or another clinical fact to fit a pathway.
Meeting a BMI or health-history criterion does not replace licensed-prescriber review, product-specific safety screening, an accurate prior authorization, or successful pharmacy processing.
CMS says beneficiaries using a GLP-1 for a Part D-coverable diagnosis do not qualify for Bridge coverage of that prescription even if they otherwise meet Bridge criteria.

Injection and tablet identity

The Bridge currently lists both Wegovy route families, but route still matters

The June 18, 2026 manufacturer label includes Wegovy semaglutide injection and Wegovy semaglutide tablets. CMS currently says all Wegovy formulations are available through the Bridge for eligible weight-management beneficiaries and publishes specified National Drug Codes. That coverage statement does not make injection and tablets interchangeable: they have route-specific routines, presentations, age and indication details, instructions, and pharmacy claims. A route change requires clinician and pharmacy coordination rather than an online conversion rule.

Ask the prescriber and pharmacy to confirm branded Wegovy, injection or tablets, the exact package or National Drug Code, quantity, authorization pathway, and accepted claim.
Do not apply injection instructions to tablets, tablet timing to injections, or a previous package’s storage and refill assumptions to a different presentation.
Do not describe Ozempic, Rybelsus, compounded semaglutide, or a no-prescription product as the same Medicare-covered Wegovy package.

What the $50 amount means

The Bridge copay has limits and is not every Medicare Wegovy price

CMS describes a $50 copay for a monthly supply furnished to an eligible beneficiary through the Medicare GLP-1 Bridge. CMS also says Bridge coverage occurs outside the Part D benefit payment flow, the $50 does not count toward true out-of-pocket costs under the Part D plan, and low-income cost-sharing subsidies do not apply to the Bridge copay. Wegovy obtained for a Part D-coverable indication follows the plan’s formulary, utilization-management, exception, pharmacy, and cost-sharing rules instead. Separate clinical services are not automatically included in a medication copay.

Ask whether the quote is for a Bridge claim, a basic Part D claim, cash-pay Wegovy, a clinician visit, or a bundled telehealth service.
Confirm the participating or preferred pharmacy, claim result, monthly-supply definition, refill timing, authorization period, renewal rules, and costs outside the medication claim.
Avoid ads that promise “Wegovy for $50” without checking Part D enrollment, current clinical criteria, prior authorization, exact product, pharmacy processing, and separate fees.

Denials and exceptions

Match the written response to the correct correction or review process

A Wegovy request can fail because the Bridge criteria were not met, the request belongs under basic Part D, information is missing, the product is non-formulary, prior authorization or utilization management applies, the pharmacy or package is not eligible, or another claim rule was triggered. CMS says the Bridge does not remove Part D appeal and exception rights. The prescriber can provide an accurate supporting statement when the rules allow, but neither an exception request nor telehealth enrollment guarantees coverage.

Get the complete denial, coverage notice, or claim response and record the exact product, route, indication, reason, date, deadline, and standard or expedited instructions.
Use truthful medical records and clinician rationale; do not invent a diagnosis, cardiovascular event, BMI, treatment failure, adverse effect, or contraindication.
Do not stop, restart, overlap, borrow, or switch Wegovy or another glucose-lowering medicine solely because a claim failed; ask the prescribing clinician for a safe interim plan.

Branded, compounded, and online access

Compounded semaglutide is not Bridge-listed Wegovy

The CMS product list names branded products and specific National Drug Codes. A patient-specific compounded semaglutide prescription is not Wegovy, is not an FDA-approved finished drug product, and should not be represented as a Bridge-covered tablet or injection. Peptide12 lists clinician-reviewed Wegovy and compounded semaglutide injection pathways, but medical eligibility, a prescription, Medicare or Bridge approval, pharmacy dispensing, and cost are never guaranteed.

Confirm whether an offer is branded Wegovy injection, branded Wegovy tablets, another FDA-approved medicine, or a patient-specific compounded preparation.
Reject no-prescription checkout, hidden pharmacy identity, research-use semaglutide sold for human treatment, copied authorization answers, guaranteed Medicare approval, or compounded medication marketed as FDA approved.
Before treatment, verify clinician licensure, product and route, dispensing pharmacy, label, storage, supplies when applicable, follow-up, adverse-event contact, refill terms, cancellation terms, and total cost.

Patient safety checklist

Questions to ask about Medicare coverage for Wegovy in 2026

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the prescription for branded Wegovy injection or branded Wegovy tablets, and which exact package or National Drug Code will the pharmacy process?

✓

Is Wegovy prescribed solely for weight management, cardiovascular-risk reduction, qualifying MASH treatment, or another documented purpose?

✓

Should the request use the Medicare GLP-1 Bridge or the basic Part D benefit, and where is that decision documented?

✓

Does the current CMS prior-authorization form show that the adult Bridge criteria are met without changing or omitting clinical facts?

✓

What did the plan, Bridge processor, or pharmacy return, and is the next action missing information, prior authorization, an exception, an appeal, or a claim correction?

✓

What medication cost, clinician fee, laboratory cost, supplies, shipping, follow-up, and renewal expense are included or excluded from the quote?

✓

Which medicines, diabetes treatments, health conditions, pregnancy plans, procedures, and current Wegovy label warnings need clinician review?

✓

If branded access is unavailable, are alternatives explained without calling compounded semaglutide FDA approved, Bridge covered, generic Wegovy, or automatically equivalent?

FAQs

Short answers for patients

Does Medicare cover Wegovy for weight loss in 2026?

Some eligible adults with Part D may obtain Bridge-listed Wegovy injection or tablets for weight management through the Medicare GLP-1 Bridge after a clinician-submitted prior authorization confirms current CMS criteria. Part D enrollment, a prescription, or qualifying BMI does not by itself guarantee eligibility or a paid claim.

Does the Medicare GLP-1 Bridge include both Wegovy injection and tablets?

Yes. CMS currently lists Wegovy injection and tablets and says all Wegovy formulations are available to eligible Bridge beneficiaries. Confirm the current product and National Drug Code list, route, package, and pharmacy claim because CMS says the list may be updated.

Does Medicare cover Wegovy for cardiovascular-risk reduction?

CMS identifies Wegovy used to reduce major cardiovascular-event risk in adults with established cardiovascular disease and overweight or obesity as a use coverable under basic Part D. That prescription goes through the Part D plan rather than the weight-management Bridge, and formulary, authorization, exception, pharmacy, and cost rules can vary.

Does Medicare cover Wegovy for MASH?

CMS identifies qualifying noncirrhotic MASH with moderate-to-advanced fibrosis as Part D-coverable. The current manufacturer label gives that accelerated-approval indication to Wegovy injection in adults, not to Wegovy tablets. Coverage is not automatic; confirm diagnosis, route, label fit, plan rules, authorization, and the written claim decision.

Is Wegovy $50 a month for every Medicare beneficiary?

No. CMS describes a $50 copay only for a monthly supply furnished to an eligible beneficiary through the Medicare GLP-1 Bridge. The patient must have Part D, meet current adult clinical criteria, obtain prior authorization, and receive an eligible product through the required processing. Part D claims and separate clinical services can cost differently.

Does the $50 Bridge copay count toward Part D out-of-pocket costs?

CMS says Bridge coverage is outside the Part D benefit payment flow and the $50 copay does not count toward the beneficiary’s true out-of-pocket costs under the Part D plan. CMS also says low-income cost-sharing subsidies do not apply to that Bridge copay.

Can a child with a Wegovy prescription use the Medicare GLP-1 Bridge?

The current CMS Bridge criteria require the beneficiary to be at least 18. That is separate from the manufacturer label, which includes a Wegovy injection weight-management indication for some patients age 12 and older. Product labeling does not override the Bridge’s adult eligibility rule.

Does Medicare cover compounded semaglutide as Wegovy?

Do not treat them as the same product. The Bridge lists branded products and National Drug Codes. A patient-specific compounded semaglutide preparation is not Wegovy and is not an FDA-approved finished drug product or an automatic Medicare, Part D, or Bridge-covered substitute.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

CMS: Medicare GLP-1 Bridge information and FAQs for Part D plans CMS: Medicare GLP-1 Bridge overview — started July 1, 2026 DailyMed: Current manufacturer Wegovy injection and tablet prescribing information — updated June 18, 2026 CMS: Medicare Part D formulary and utilization-management exceptions Medicare: Compare Medicare health and drug plans FDA: Compounding and the FDA — Questions and Answers Peptide12: Wegovy Peptide12: Wegovy prior authorization Peptide12: Wegovy savings card Peptide12: Oral Wegovy cost Peptide12: GLP-1 step therapy Peptide12: Insurance, HSA, and FSA questions Peptide12: Compounded semaglutide injection Peptide12: Zepbound Medicare coverage Peptide12: How online peptide therapy works